Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma

2.

Chapuy

B

,

Stewart

C

,

Dunford

AJ

, et al.

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

.

Nat Med

.

2018

;

24

(

5

):

679

-

690

.

3.

Schmitz

R

,

Wright

GW

,

Huang

DW

, et al.

Genetics and pathogenesis of diffuse large B-cell lymphoma

.

N Engl J Med

.

2018

;

378

(

15

):

1396

-

1407

.

4.

Steen

CB

,

Luca

BA

,

Esfahani

MS

, et al.

The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma

.

Cancer Cell

.

2021

;

39

(

10

):

1422

-

1437.e10

.

5.

Gerber-Ferder

Y

,

Cosgrove

J

,

Duperray-Susini

A

, et al.

Breast cancer remotely imposes a myeloid bias on haematopoietic stem cells by reprogramming the bone marrow niche

.

Nat Cell Biol

.

2023

;

25

(

12

):

1736

-

1745

.

6.

Kotlov

N

,

Bagaev

A

,

Revuelta

MV

, et al.

Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures

.

Cancer Discov

.

2021

;

11

(

6

):

1468

-

1489

.

7.

Nicholas

NS

,

Apollonio

B

,

Ramsay

AG

.

Tumor microenvironment (TME)-driven immune suppression in B cell malignancy

.

Biochim Biophys Acta

.

2016

;

1863

(

3

):

471

-

482

.

8.

Reddy

A

,

Zhang

J

,

Davis

NS

, et al.

Genetic and functional drivers of diffuse large B cell lymphoma

.

Cell

.

2017

;

171

(

2

):

481

-

494.e15

.

9.

Pasqualucci

L

,

Dalla-Favera

R

.

The genetic landscape of diffuse large B-cell lymphoma

.

Semin Hematol

.

2015

;

52

(

2

):

67

-

76

.

10.

Calon

A

,

Tauriello

DV

,

Batlle

E

.

TGF-beta in CAF-mediated tumor growth and metastasis

.

Semin Cancer Biol

.

2014

;

25

:

15

-

22

.

11.

Zhang

MC

,

Tian

S

,

Fu

D

, et al.

Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial

.

Cancer Cell

.

2023

;

41

(

10

):

1705

-

1716.e5

.

12.

Dufva

O

,

Polonen

P

,

Bruck

O

, et al.

Immunogenomic landscape of hematological malignancies

.

Cancer Cell

.

2020

;

38

(

3

):

424

-

428

.

13.

Wellenstein

MD

,

de Visser

KE

.

Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape

.

Immunity

.

2018

;

48

(

3

):

399

-

416

.

14.

Calvo-Vidal

MN

,

Zamponi

N

,

Krumsiek

J

, et al.

Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas

.

Cancer Res

.

2021

;

81

(

20

):

5202

-

5216

.

15.

Fangazio

M

,

Ladewig

E

,

Gomez

K

, et al.

Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma

.

Proc Natl Acad Sci U S A

.

2021

;

118

(

22

):

e2104504118

.

16.

Nijland

M

,

Veenstra

RN

,

Visser

L

, et al.

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

.

Oncoimmunology

.

2017

;

6

(

4

):

e1295202

.

17.

Dersh

D

,

Phelan

JD

,

Gumina

ME

, et al.

Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas

.

Immunity

.

2021

;

54

(

1

):

116

-

131.e10

.

18.

Okosun

J

,

Bodor

C

,

Wang

J

, et al.

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

.

Nat Genet

.

2014

;

46

(

2

):

176

-

181

.

19.

Challa-Malladi

M

,

Lieu

YK

,

Califano

O

, et al.

Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma

.

Cancer Cell

.

2011

;

20

(

6

):

728

-

740

.

20.

Godfrey

J

,

Tumuluru

S

,

Bao

R

, et al.

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype

.

Blood

.

2019

;

133

(

21

):

2279

-

2290

.

21.

Boice

M

,

Salloum

D

,

Mourcin

F

, et al.

Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells

.

Cell

.

2016

;

167

(

2

):

405

-

418.e13

.

22.

Chiodin

G

,

Allen

JD

,

Bryant

DJ

, et al.

Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior

.

Blood

.

2021

;

138

(

17

):

1570

-

1582

.

23.

Ennishi

D

,

Healy

S

,

Bashashati

A

, et al.

TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

.

Nat Med

.

2020

;

26

(

4

):

577

-

588

.

24.

Mandato

E

,

Calabretta

E

,

Bai

G

, et al.

Cd70 Deficiency Impairs CD4 + and CD8 + T-cell immune surveillance in Bcl6-driven diffuse large B-cell lymphomas [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1624

.

25.

Berglund

A

,

Mills

M

,

Putney

RM

,

Hamaidi

I

,

Mule

J

,

Kim

S

.

Methylation of immune synapse genes modulates tumor immunogenicity

.

J Clin Invest

.

2020

;

130

(

2

):

974

-

980

.

26.

Jiang

XN

,

Yu

BH

,

Yan

WH

,

Lee

J

,

Zhou

XY

,

Li

XQ

.

Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression

.

Oncoimmunology

.

2020

;

9

(

1

):

1683346

.

27.

Choi

IK

,

Wang

Z

,

Ke

Q

, et al.

Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses

.

Proc Natl Acad Sci U S A

.

2018

;

115

(

4

):

E686

-

E695

.

28.

Morin

RD

,

Mendez-Lago

M

,

Mungall

AJ

, et al.

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

.

Nature

.

2011

;

476

(

7360

):

298

-

303

.

29.

Cerchietti

LC

,

Hatzi

K

,

Caldas-Lopes

E

, et al.

BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy

.

J Clin Invest

.

2010

;

120

(

12

):

4569

-

4582

.

30.

Green

MR

,

Kihira

S

,

Liu

CL

, et al.

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation

.

Proc Natl Acad Sci U S A

.

2015

;

112

(

10

):

E1116

-

1125

.

31.

Hashwah

H

,

Schmid

CA

,

Kasser

S

, et al.

Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth

.

Proc Natl Acad Sci U S A

.

2017

;

114

(

36

):

9701

-

9706

.

32.

Ennishi

D

,

Takata

K

,

Beguelin

W

, et al.

Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition

.

Cancer Discov

.

2019

;

9

(

4

):

546

-

563

.

33.

Jiang

Y

,

Ortega-Molina

A

,

Geng

H

, et al.

CREBBP inactivation promotes the development of HDAC3-dependent lymphomas

.

Cancer Discov

.

2017

;

7

(

1

):

38

-

53

.

34.

Taura

M

,

Eguma

A

,

Suico

MA

, et al.

p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines

.

Mol Cell Biol

.

2008

;

28

(

21

):

6557

-

6567

.

35.

Thiem

A

,

Hesbacher

S

,

Kneitz

H

, et al.

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

.

J Exp Clin Cancer Res

.

2019

;

38

(

1

):

397

.

36.

Menendez

D

,

Shatz

M

,

Azzam

K

,

Garantziotis

S

,

Fessler

MB

,

Resnick

MA

.

The Toll-like receptor gene family is integrated into human DNA damage and p53 networks

.

PLoS Genet

.

2011

;

7

(

3

):

e1001360

.

37.

Vogiatzi

F

,

Brandt

DT

,

Schneikert

J

, et al.

Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5

.

Proc Natl Acad Sci U S A

.

2016

;

113

(

52

):

E8433

-

E8442

.

38.

Ennishi

D

,

Jiang

A

,

Boyle

M

, et al.

Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma

.

J Clin Oncol

.

2019

;

37

(

3

):

190

-

201

.

39.

Smith

BAH

,

Deutzmann

A

,

Correa

KM

, et al.

MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint

.

Proc Natl Acad Sci U S A

.

2023

;

120

(

11

):

e2215376120

.

40.

Casey

SC

,

Tong

L

,

Li

Y

, et al.

MYC regulates the antitumor immune response through CD47 and PD-L1

.

Science

.

2016

;

352

(

6282

):

227

-

231

.

41.

Atsaves

V

,

Tsesmetzis

N

,

Chioureas

D

, et al.

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

.

Leukemia

.

2017

;

31

(

7

):

1633

-

1637

.

42.

Higashi

M

,

Momose

S

,

Takayanagi

N

, et al.

CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma

.

J Pathol Clin Res

.

2022

;

8

(

4

):

340

-

354

.

43.

Lujambio

A

,

Akkari

L

,

Simon

J

, et al.

Non-cell-autonomous tumor suppression by p53

.

Cell

.

2013

;

153

(

2

):

449

-

460

.

44.

Quigley

D

,

Silwal-Pandit

L

,

Dannenfelser

R

, et al.

Lymphocyte invasion in IC10/basal-like breast tumors is associated with wild-type TP53

.

Mol Cancer Res

.

2015

;

13

(

3

):

493

-

501

.

45.

Souza

L

,

Faletti

A

,

Verissimo

CP

,

Stelling

MP

,

Borges

HL

.

p53 signaling on microenvironment and its contribution to tissue chemoresistance

.

Membranes (Basel)

.

2022

;

12

(

2

):

202

.

46.

Coppe

JP

,

Patil

CK

,

Rodier

F

, et al.

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor

.

PLoS Biol

.

2008

;

6

(

12

):

2853

-

2868

.

47.

Ghosh

M

,

Saha

S

,

Bettke

J

, et al.

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

.

Cancer Cell

.

2021

;

39

(

4

):

494

-

508.e5

.

48.

Celay

J

,

Recalde

M

,

Revuelta

MV

, et al.

Remodeling of the immune microenvironment by oncogenic MYD88 dictates immunotherapy responses across indolent and aggressive B-cell lymphomas [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

431

.

49.

Zimmerli

D

,

Brambillasca

CS

,

Talens

F

, et al.

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

.

Nat Commun

.

2022

;

13

(

1

):

6579

.

50.

Lee

KM

,

Lin

CC

,

Servetto

A

, et al.

Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer

.

Cancer Immunol Res

.

2022

;

10

(

7

):

829

-

843

.

51.

Wu

SY

,

Xiao

Y

,

Wei

JL

, et al.

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer

.

J Immunother Cancer

.

2021

;

9

(

7

):

e002528

.

52.

Young

A

,

Mittal

D

,

Stagg

J

,

Smyth

MJ

.

Targeting cancer-derived adenosine: new therapeutic approaches

.

Cancer Discov

.

2014

;

4

(

8

):

879

-

888

.

53.

Hasko

G

,

Sitkovsky

MV

,

Szabo

C

.

Immunomodulatory and neuroprotective effects of inosine

.

Trends Pharmacol Sci

.

2004

;

25

(

3

):

152

-

157

.

54.

Huang

YH

,

Cai

K

,

Xu

PP

, et al.

CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis

.

Signal Transduct Target Ther

.

2021

;

6

(

1

):

10

.

55.

Turi

M

,

Anilkumar Sithara

A

,

Hofmanova

L

, et al.

Transcriptome analysis of diffuse large B-cell lymphoma cells inducibly expressing MyD88 L265P mutation identifies upregulated CD44, LGALS3, NFKBIZ, and BATF as downstream targets of oncogenic NF-kappaB signaling

.

Int J Mol Sci

.

2023

;

24

(

6

):

5623

.

56.

Ngo

VN

,

Young

RM

,

Schmitz

R

, et al.

Oncogenically active MYD88 mutations in human lymphoma

.

Nature

.

2011

;

470

(

7332

):

115

-

119

.

57.

Kakarla

M

,

ChallaSivaKanaka

S

,

Hayward

SW

,

Franco

OE

.

Race as a contributor to stromal modulation of tumor progression

.

Cancers

.

2021

;

13

(

11

):

2656

.

58.

Assis-Mendonca

GR

,

Fattori

A

,

Rocha

RM

, et al.

Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma

.

BMC Cancer

.

2021

;

21

(

1

):

209

.

59.

Cerhan

JR

,

Wang

S

,

Maurer

MJ

, et al.

Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival

.

Blood

.

2007

;

109

(

12

):

5439

-

5446

.

60.

Habermann

TM

,

Wang

SS

,

Maurer

MJ

, et al.

Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era

.

Blood

.

2008

;

112

(

7

):

2694

-

2702

.

61.

Nielsen

KR

,

Steffensen

R

,

Haunstrup

TM

, et al.

Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma

.

Leuk Lymphoma

.

2015

;

56

(

12

):

3257

-

3266

.

62.

Tang

W

,

Wallace

TA

,

Yi

M

, et al.

IFNL4-DeltaG allele is associated with an interferon signature in tumors and survival of african-american men with prostate cancer

.

Clin Cancer Res

.

2018

;

24

(

21

):

5471

-

5481

.

63.

Shenoy

PJ

,

Malik

N

,

Nooka

A

, et al.

Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States

.

Cancer

.

2011

;

117

(

11

):

2530

-

2540

.

64.

Lee

MJ

,

Koff

JL

,

Switchenko

JM

, et al.

Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma

.

Cancer

.

2020

;

126

(

15

):

3493

-

3503

.

65.

Rozhok

AI

,

Salstrom

JL

,

DeGregori

J

.

Stochastic modeling indicates that aging and somatic evolution in the hematopoetic system are driven by non-cell-autonomous processes

.

Aging (Albany NY)

.

2014

;

6

(

12

):

1033

-

1048

.

66.

Fane

M

,

Weeraratna

AT

.

How the ageing microenvironment influences tumour progression

.

Nat Rev Cancer

.

2020

;

20

(

2

):

89

-

106

.

67.

Jaiswal

S

,

Fontanillas

P

,

Flannick

J

, et al.

Age-related clonal hematopoiesis associated with adverse outcomes

.

N Engl J Med

.

2014

;

371

(

26

):

2488

-

2498

.

68.

Libby

P

,

Sidlow

R

,

Lin

AE

, et al.

Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week

.

J Am Coll Cardiol

.

2019

;

74

(

4

):

567

-

577

.

69.

Fuster

JJ

,

MacLauchlan

S

,

Zuriaga

MA

, et al.

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

.

Science

.

2017

;

355

(

6327

):

842

-

847

.

70.

Wang

W

,

Liu

W

,

Fidler

T

, et al.

Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice

.

Circ Res

.

2018

;

123

(

11

):

e35

-

e47

.

71.

Marullo

R

,

Revuelta

MV

,

Béguelin

W

,

Lara-Garcia

J

,

Cerchietti

L

.

Aging-associated epigenetic reprogramming alters the germinal center reaction and targets pathways related to lymphomagenesis [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

676

.

72.

Franceschi

C

,

Garagnani

P

,

Parini

P

,

Giuliani

C

,

Santoro

A

.

Inflammaging: a new immune-metabolic viewpoint for age-related diseases

.

Nat Rev Endocrinol

.

2018

;

14

(

10

):

576

-

590

.

73.

Zhu

X

,

Chen

Z

,

Shen

W

, et al.

Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention

.

Signal Transduct Target Ther

.

2021

;

6

(

1

):

245

.

74.

Leonardi

GC

,

Accardi

G

,

Monastero

R

,

Nicoletti

F

,

Libra

M

.

Ageing: from inflammation to cancer

.

Immun Ageing

.

2018

;

15

:

1

.

75.

Kanesvaran

R

,

Cordoba

R

,

Maggiore

R

.

Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research

.

Am Soc Clin Oncol Educ Book

.

2018

;

38

:

400

-

414

.

76.

Pan

H

,

Jiang

Y

,

Boi

M

, et al.

Epigenomic evolution in diffuse large B-cell lymphomas

.

Nat Commun

.

2015

;

6

:

6921

.

77.

Clozel

T

,

Yang

S

,

Elstrom

RL

, et al.

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma

.

Cancer Discov

.

2013

;

3

(

9

):

1002

-

1019

.

78.

Stelling

A

,

Wu

CT

,

Bertram

K

, et al.

Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma

.

Blood Adv

.

2019

;

3

(

20

):

3020

-

3032

.

79.

Sangaletti

S

,

Iannelli

F

,

Zanardi

F

, et al.

Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces

.

EBioMedicine

.

2020

;

61

:

103055

.

80.

Yang

R

,

Cheng

S

,

Luo

N

, et al.

Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis

.

Genome Biol

.

2019

;

21

(

1

):

2

.

81.

Zou

Q

,

Wang

X

,

Ren

D

, et al.

DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer

.

J Immunother Cancer

.

2021

;

9

(

9

):

e002671

.

82.

Ghoneim

HE

,

Fan

Y

,

Moustaki

A

, et al.

De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation

.

Cell

.

2017

;

170

(

1

):

142

-

157.e19

.

83.

Stephen

TL

,

Payne

KK

,

Chaurio

RA

, et al.

SATB1 expression governs epigenetic repression of PD-1 in tumor-reactive T cells

.

Immunity

.

2017

;

46

(

1

):

51

-

64

.

84.

Dogra

P

,

Ghoneim

HE

,

Abdelsamed

HA

,

Youngblood

B

.

Generating long-lived CD8(+) T-cell memory: insights from epigenetic programs

.

Eur J Immunol

.

2016

;

46

(

7

):

1548

-

1562

.

85.

Xia

M

,

Wang

B

,

Wang

Z

,

Zhang

X

,

Wang

X

.

Epigenetic regulation of NK cell-mediated antitumor immunity

.

Front Immunol

.

2021

;

12

:

672328

.

86.

Sahakian

E

,

Powers

JJ

,

Chen

J

, et al.

Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function

.

Mol Immunol

.

2015

;

63

(

2

):

579

-

585

.

87.

Youn

JI

,

Kumar

V

,

Collazo

M

, et al.

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer

.

Nat Immunol

.

2013

;

14

(

3

):

211

-

220

.

88.

Kittan

NA

,

Allen

RM

,

Dhaliwal

A

, et al.

Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes

.

PLoS One

.

2013

;

8

(

10

):

e78045

.

89.

Albrengues

J

,

Bertero

T

,

Grasset

E

, et al.

Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts

.

Nat Commun

.

2015

;

6

:

10204

.

90.

Abhimanyu

,

Ontiveros

CO

,

Guerra-Resendez

RS

, et al.

Reversing post-infectious epigenetic-mediated immune suppression

.

Front Immunol

.

2021

;

12

:

688132

.

91.

Zhang

MC

,

Fang

Y

,

Xu

PP

, et al.

Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study

.

Clin Transl Med

.

2021

;

11

(

12

):

e584

.

92.

Revuelta

M

,

Cerchietti

L

. Epigenetic priming—fact or falacy?. In:

Gray

SG

, eds.

Epigenetic Cancer Therapy

. 2nd ed..

Academic Press

;

2023

:

675

-

685

.

93.

Zhu

S

,

Gokhale

S

,

Jung

J

, et al.

Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets - beyond B lymphocytes

.

Front Cell Dev Biol

.

2021

;

9

:

727531

.

94.

Chiu

H

,

Trisal

P

,

Bjorklund

C

, et al.

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

.

Br J Haematol

.

2019

;

185

(

2

):

240

-

253

.

95.

Apollonio

B

,

Spada

F

,

Petrov

N

, et al.

Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

.

J Clin Invest

.

2023

;

133

(

13

):

e166070

.

96.

Xu-Monette

ZY

,

Li

Y

,

Snyder

T

, et al.

Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL

.

Clin Cancer Res

.

2023

;

29

(

23

):

4808

-

4821

.